← Back to patent-cliff list
Sulfotanshinone sodium
Tier C — Watch / tradeSulfotanshinone sodium
-
Originator
1995
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：Coronary artery disease, Myocardial infarction, Angina pectoris
Regional status
US
-
EU
-
China
Approved
1995-01-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sulfotanshinone sodium?
Approved indications include: Coronary artery disease, Myocardial infarction, Angina pectoris.
When does the Sulfotanshinone sodium patent expire?
No public expiry year is available for Sulfotanshinone sodium yet; this page updates once verified.
How do I get a quote for Sulfotanshinone sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-04